Actinium Pharmaceuticals
ATNM
72 hedge funds and large institutions have $15.9M invested in Actinium Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 18 closing their positions.
315% more call options, than puts
Call options by funds: $170K | Put options by funds: $41K
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
2.82% more ownership
Funds ownership: 24.34% → 27.16% (+2.8%)
3% less funds holding
Funds holding: 74 → 72 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
70% less capital invested
Capital invested by funds: $53.6M → $15.9M (-$37.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.79M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.42M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$852K |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
+$676K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$576K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.05M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$882K |
| 3 |
BC
BIT Capital
Berlin,
Germany
|
-$664K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$556K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$280K |
ATNM Hedge Fund Activity: Q3 2024 in Review
72 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2024, worth a combined $15.9M — down 70% from $53.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ATNM and 16 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 25 added.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $1.79M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $1.05M sold.
- 72 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2024, down from 74 in Q2 2024.
- Funds reported $15.9M of Actinium Pharmaceuticals stock for Q3 2024, down 70% quarter-over-quarter.
- 16 funds opened new Actinium Pharmaceuticals positions in Q3 2024 and 18 closed out, a net change of -2 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2024 was Acadian Asset Management, an estimated $1.79M added.
- The largest Actinium Pharmaceuticals seller in Q3 2024 was Schonfeld Strategic Advisors, an estimated $1.05M sold.
Based on aggregated 13F filings for Q3 2024.